Search results
Results from the WOW.Com Content Network
A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to meglitinide for the treatment of type 2 diabetes.
Repaglinide is a medication used in addition to diet and exercise for blood sugar control in type 2 diabetes. [1] The mechanism of action of repaglinide involves promoting insulin release from β-islet cells of the pancreas; like other antidiabetic drugs, a main side effect concern is hypoglycemia. [ 1 ]
Glimepiride was patented in 1979 and approved for medical use in 1995. [5] It is available as a generic medication . [ 2 ] In 2022, it was the 64th most commonly prescribed medication in the United States, with more than 10 million prescriptions.
The average age of the patients was 57.4 years, according to the study findings. Glucagon-like peptide 1 (GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were ...
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, addiction, heart disease, and gastrointestinal problems, among others.
[2] [1] It contains the thiazolidinedione pioglitazone and the sulfonylurea glimepiride. [2] [1] It is taken by mouth. [2] [1] The most common side effects include upper respiratory tract infections (such as colds), hypoesthesia (reduced sense of touch), bone fractures, weight gain, dizziness, flatulence (gas) and edema (swelling). [1]
This is the first class of non-opioid pain medication approved to treat moderate to severe acute pain approved by the FDA in more than 20 years. FDA approves new type of non-opioid pain medication ...
DPP-4 inhibitors and GLP-1. Inhibitors of dipeptidyl peptidase 4 (DPP-4 inhibitors or gliptins) are a class of oral hypoglycemics that block the enzyme dipeptidyl peptidase-4 (DPP-4). They can be used to treat diabetes mellitus type 2. The first agent of the class – sitagliptin – was approved by the FDA in 2006. [1]